Regulatory approval

Published by the Health Service Executive. Approved

As monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

This is written in the approval document.

Reimbursement

ODMS

Citation

Sacituzumab Govitecan Therapy, 2025, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6417/794_v3_Sacituzumab_Govitecan_Therapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan